

# Listed Private Assets Fund Q4 2023 Commentary

# Portfolio Management



# **Investment Objective**

The Fund aims to produce high single digit returns, from a combination of capital appreciation and income, with a targeted annual yield of 4-5%. The investment philosophy of the Fund is founded on the premise that exposure to private assets should earn a premium over listed equities and bonds over time.

### Contact

**Heptagon Capital** 63 Brook Street, Mayfair, London W1K 4HS

Tel: +44 20 7070 1800 email <u>london@heptagon-capital.com</u> Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation.

The strategy was up +10.8% in the fourth quarter of 2023, after a powerful rally in November and December, where the fund returned +9% and +8%, respectively. This 17% increase in the value of our assets came as a result of slower inflation and a more dovish Federal Reserve. Our previous quarterly commentary contended that the catalyst needed to unlock value in our heavily discounted holdings was the prospect of lower yields. A meaningful rally in both the short and long end of the yield curve in the US, Europe and the UK provided a strong backdrop for narrowing the discounts to net asset values across our holdings.

### I Weighted Average Fund Discount



Source: Heptagon Capital, Jefferies

Our weighted average discount reached a low of -20% at the end of October, and rallied all the way back to -12%, which is still well below our typical, expected range of -4% to -5%. The rally was driven primarily by our Real Estate exposure in the US and the UK. REITS outperformed most assets during this rally and generated strong, double-digit returns across our holdings.

Starting with Alexandria Real Estate Equities, our life science property specialist, this position returned +27% during Q4. Alexandria is celebrating its 30<sup>th</sup> anniversary as the first and only publicly traded pure-play life science REIT. The company created the first-ever REIT uniquely focused on the critically important life

Past performance is no guide to future performance, and the value of investments and income from them can fall as well as rise

science industry with its founding on January 5<sup>th</sup> 1994. Over the past three decades, the company has transformed life science real estate from a specialty niche to a compelling mainstream asset class. It has a total market capitalisation of \$28.3 billion and an asset base in North America of 75.1 million square feet as of September 30, 2023. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science, agtech, and advanced technology mega campuses that provide innovative tenants with highly dynamic and collaborative environments. This, in turn, helps their tenants to successfully recruit and retain world-class talent and foster productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation, and technology companies through its venture capital platform. Half of all FDA-approved therapies since 2013 have come from Alexandria's tenants, demonstrating the company's meaningful impact on human health. Alexandria's unique business model and diligent underwriting ensures a high-quality and diverse tenant base, resulting in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. We continue to believe that Alexandria will be a strong driver of returns for our strategy going forward, with a 5.7% position size as of December 31<sup>st</sup>.

The best-performing holding during the fourth quarter was the PRS REIT, with a +28% total return. It is the UK's largest developer of family rental homes, and the company staged a comeback following a challenging environment, as investors anticipated its dividend to be covered as revenue increased. The stock has also been buoyed by hopes that interest rates will fall in 2024, relieving some of the pressure on its finances and property valuations. PRS's annual and first-quarter results, published together in October, showed that the Trust was achieving significant scale and benefiting from strong rental growth thanks to the national shortage of affordable homes. PRS passed a landmark in April when it built its 5,000th home. The portfolio's expansion boosted the company's rental income, and total revenue was 17% higher at £40.2m in the year to June 30<sup>th</sup>. Like-for-like rents rose by 7.5% also. Homes re-let to new tenants achieved even higher rental growth of 12%. We believe that the lack of affordable housing and the prohibitive cost of buying a house given the current level of interest rates should support the outlook for the private rental sector in the UK. The company's discount went as low as 45% in October and has since narrowed back to a 30% discount. PRS was a 5% position as of December 31<sup>st</sup>.



# PRS REIT: NAV & Share Price - 5 Year

Source: FactSet, Hargreaves Lansdown


Our Private Equity holdings also enjoyed a strong re-rating in Q4. 3i Group returned +18% during this period as the fundamentals for its largest asset, discount retailer group Action, remain strong and on track to deliver another strong double-digit growth return in 2023. It is worth noting that we managed to accumulate some shares at a discount to net asset value in contrast to the current 20% premium on offer.

The worst performer during the quarter was our holding in music royalty company Hipgnosis, with a negative -10% total return. We have covered this holding extensively in our recent commentaries, but the bottom line is that the Hipgnosis

Past performance is no guide to future performance, and the value of investments and income from them can fall as well as rise

management has been asked to propose alternative terms for future advisory arrangements, and if they fail to do so, the Board will explore alternative proposals. In our view, the current -50% discount to net asset value reflects current shareholders' distrust of management rather than the true value of the underlying assets. Hipgnosis is now one of our smallest positions with a +3% weight.

Finally, our position in Yellow Cake, the uranium investment company, continued to deliver strong returns with a +10% total return for Q4. We believe nuclear energy has a key role in lowering CO2 emissions for decades to come and that the lack of investment in mining and enrichment projects has created a supply and demand imbalance of epic proportions. We have been taking profits and have trimmed our positions as the price increased and have generated a 60%+ since our first purchased in 2022.



#### Source: Bloomberg

We enter 2024 with a pragmatic yet optimistic view of our underlying assets. Slower inflation, combined with looser financial conditions and decent economic growth, should help support our sectors and holdings, particularly if rates have truly peaked. With insight, the magnitude of the bond market rally in Q4 was probably discounting too many rate cuts going into 2024. Those aggressive assumptions are now being tested by the markets, but we believe that on balance, the backdrop for our strategy is very attractive given the above conditions and the level of discount on offer for many of our holdings. We expect our Real Estate holdings to continue their strong recovery and deliver better adjusted return as financial conditions normalise following some volatile years.

We would like to thank our investors for their patience and confidence.

Kind regards,

Arnaud Gandon, Portfolio Manager



# I Important Information

Past performance is not an indication or guarantee of future performance and no representation or warranty is made regarding future performance. This communication is for information purposes only. It is not an invitation or inducement to engage in investment activity.

The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy or sell or otherwise transact in any investments.

The contents of this document are based upon sources of information which Heptagon Capital believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document.

The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital's prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital's prior written consent.

Heptagon Capital Limited has issued this communication as investment manager for Heptagon Fund ICAV, and is licensed to conduct investment services by the Malta Financial Services Authority. Heptagon Capital LLP, acting as Distributor, is authorised and regulated in the UK by the Financial Conduct Authority.

## Risk Warnings

The Fund is subject to special risk considerations including geographic concentration risk, portfolio concentration risk and operational risk. The investment return and principal value of an investment will fluctuate so that the investor's shares, when redeemed, may be worth more or less than their original cost. Any investor should consider the investment objectives, risks and charges and expenses of the fund carefully before investing. Where an investment is denominated in a currency other than the investor's currency, changes in rates of exchange may have an adverse effect on the value, price of, or income derived from the investment.

## SFDR

The Fund takes sustainability risks into account within the investment process, and this is disclosed in accordance with Article 6 requirements of the Sustainable Finance Disclosure Regulation ('SFDR') in the Fund's <u>Prospectus</u>. However, the Fund does not have as its objective sustainable investment and does not promote environmental or social characteristics for the purposes of the SFDR. Sustainability risks may occur in a manner that is not anticipated by the Sub-Investment Manager, there may be a sudden, material negative impact on the value of an investment and hence the returns of the Fund. As a result of the assessment of the impact of sustainability risks on the returns of the Fund, the Sub-Investment Manager aims to identified that the Fund may be exposed to sustainability risks and will aim to mitigate those risks.

Partnership No: OC307355 Registered in England and Wales

Authorised & Regulated by the Financial Conduct Authority (FRN: 403304)

## **Disclaimers**

Source: MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.msci.com)

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and S&P Global Market Intelligence ("S&P") and is licensed for use by Heptagon Fund ICAV. Neither MSCI, S&P, nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

For all definitions of the financial terms used within this document, please refer to the glossary on our website: <u>https://www.heptagon-capital.com/glossary</u>

Heptagon Capital, 63 Brook Street, Mayfair, London W1K 4HS Tel: +44 20 7070 1800 (FRN 403304) Authorised & Regulated by the Financial Conduct Authority in the UK 12 Endeavour Square, London

Past performance is no guide to future performance, and the value of investments and income from them can fall as well as rise